Advanced

AJNR - American Journal of Neuroradiology

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Matheus, M. G. Articles by Morris, D. E. Search for Related Content PubMed PubMed Citation Articles by Matheus, M. G. Articles by Morris, D. E.

American Journal of Neuroradiology 25:1211-1217, August 2004
© 2004 American Society of Neuroradiology

BRAIN

CT and MR Imaging after Placement of the GliaSite Radiation Therapy System to Treat Brain Tumor: Initial Experience

Maria G. Matheus^a, Mauricio Castillo^a, Matthew Ewend^b, Jeffrey K. Smith^a, Lester Knock^a, Sharon Cush^b and David E. Morris^c

^a Department of Radiology, University of North Carolina School of Medicine, Chapel Hill
^b Department of Neurosurgery, University of North Carolina School of Medicine, Chapel Hill
^c Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill

Address reprint requests to Mauricio Castillo, MD, Department of Radiology, University of North Carolina, Chapel Hill, NC 27599

BACKGROUND AND PURPOSE: The GliaSite system delivers local, high radiation after brain tumor resection. We describe the imaging appearance of the device and the changes it causes.

METHODS: Eight patients with brain tumors were treated with this system. After surgery, all underwent MR imaging, and one underwent CT. Five were examined 1 month after radioactive unloading and every 2 months thereafter (total, 6–9 months). Initial studies were assessed for balloon appearance and complications; subsequent studies, for signal intensity and enhancement. Three patients underwent multivoxel proton MR spectroscopy, and one underwent MR perfusion study. Spectra were reviewed for metabolites suggesting tumor; perfusion studies were reviewed for increased relative cerebral blood volume and flow.

RESULTS: CT showed the hyperattenuating balloon with considerable artifact. All MR images showed the device and adjacent brain. Follow-up studies showed enhancement and T2 hyperintensity in five patients. In one, enhancement progressively disappeared with no evidence of tumor recurrence. Another patient had progressive enhancement and low relative cerebral blood volume and flow; biopsy showed necrosis and inflammation. One patient had progressive enhancement and high choline levels (proved anaplastic astrocytoma). In another, T2 signal intensity and contrast enhancement progressed owing to tumor and bacterial infection. The last patient had a high choline level (proved radionecrosis); enhancement progressed over 5 months. In three, the device was removed early because of bleeding, mass effect, and therapeutic changes (no follow-up).

CONCLUSION: Good balloon visualization was possible with MR imaging. After brachytherapy, all patients developed T2 hyperintensity; stable or progressive enhancement occurred with tumor recurrence and radionecrosis. High choline levels were suggestive of, but not necessarily diagnostic of, tumor.

This article has been cited by other articles:

				M. J. van den Bent, M. A. Vogelbaum, P. Y. Wen, D. R. Macdonald, and S. M. Chang End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria J. Clin. Oncol., June 20, 2009; 27(18): 2905 - 2908. [Full Text] [PDF]